A Phase 1/2 interventional study of Placebo and TQA3605 tablets in Chronic Hepatitis b, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.
Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 1/2, and was the 7th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–60 · Healthy volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–65
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 116 across the 13 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind Phase Ib/IIa multicenter trial design was used. All eligible subjects received TQA3605 tablets/placebo plus nucleoside (acid) analogues. A total of 88 subjects were required
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
Drug: Placebo · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
50 mg of TQA3605 tablets and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
TQA3605 is taken orally 100mg once daily; Nucleoside (acid) analogues were used once daily for 48 weeks.
Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
TQA3605 is taken orally 200mg once daily; Nucleoside (acid) analogues were used once daily for 48 weeks.
Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
Placebo taken orally once daily, continue for 12 weeks. Placebo was then combined with nucleoside (acid) analogues (once daily) for 36 weeks
Drug: Placebo · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
TQA3605 was taken orally 100mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.
Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
TQA3605 was taken orally 200mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.
Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
TQA3605 was taken orally 300mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.
Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet
TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
TQA3605 inhibits viral replication.
Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
The incidence of adverse events (AEs)
The incidence of adverse events (AEs) during treatment
Time frame: Up to 48 weeks
Severity of adverse events (AEs)
The severity of adverse events (AEs) during treatment
Time frame: Up to 48 weeks
Incidence of serious adverse events (SAEs)
The incidence of serious adverse events (SAEs) during treatment
Time frame: Up to 48 weeks
Severity of serious adverse events (SAEs)
The severity of serious adverse events (SAEs) during treatment
Time frame: Up to 48 weeks
Incidence of abnormal laboratory test values
The incidence of abnormal laboratory values during treatment, e.g. triglycerides.
Time frame: Up to 48 weeks
Severity of abnormal laboratory test values
The severity of abnormal laboratory values during treatment, e.g. triglycerides.
Time frame: Up to 48 weeks
Deoxyribonucleic acid level of hepatitis B virus
Changes in hepatitis B virus deoxyribonucleic acid (HBV DNA) levels from baseline
Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study
Hepatitis B surface antigen
Changes in serum hepatitis B surface antigen (HBsAg) from baseline
Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study
Hepatitis B e antigen
Changes in serum hepatitis B e antigen (HBeAg) from baseline
Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study
Serologic clearance and/or serologic conversion of HBsAg
Proportion of subjects with HBsAg serologic clearance and/or serologic conversion
Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study
Serologic clearance and/or serologic conversion of HBeAg
Proportion of subjects with HBeAg serologic clearance and/or serologic conversion
Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study
Virological breakthrough rate
The proportion of subjects who achieved a virological breakthrough (defined as a confirmed increase of HBV DNA levels \>1.0 log10 IU/ml from the minimum during treatment).
Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study
Peak time (Tmax)
Time to reach peak blood concentration after a single dose
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Peak concentration
The highest plasma drug concentration that can be achieved after medication
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Area under blood concentration-time curve (AUC)
The amount of drug absorbed into the human circulation after a single dose can be estimated using the area under the blood concentration-time curve
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Apparent volume of distribution (Vd/F)
When a drug reaches homeostasis in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Plasma clearance
The amount of plasma that the kidneys completely clear in unit time (per minute).
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Elimination half-life
The time it takes for the plasma concentration to drop by half.
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Steady state peak time
The time required to reach peak steady-state concentration after administration
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Steady state maximum concentration
The highest blood concentration that occurs after stabilization
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Steady state minimal concentration
The lowest blood concentration that occurs after stabilization
Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQA3605
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →